TarlaCases
塔拉妥单抗病例集
| 序号 | 文章标题 | 期刊 | 年份 | 摘要一句话 |
|---|---|---|---|---|
| 1 | Atezolizumab, lurbinectedin, tarlatamab, and FOLFIRNOX in a patient with metastatic small cell carcinoma of the anal canal: A case report and review of the literature. | Seminars in oncology | 2026 | 单病例+综述转移性肛管小细胞癌患者接受 lurbinectedin+tarlatamab 后提示临床获益，支持在肠外小细胞癌中探索 DLL3 靶向治疗。 |
| 2 | Anakinra Prophylaxis for Recurrent Severe ICANS Associated With Tarlatamab in Small Cell Lung Cancer: Case Report. | JTO clinical and research reports | 2026 | 单病例报告复发 SCLC 使用 tarlatamab 反复发生重度 ICANS，预防性 anakinra 使治疗得以继续并取得包括颅内病灶在内的显著缓解。 |
| 3 | EGFR Wild-Type Sarcomatoid Carcinoma as Acquired Resistance to Tarlatamab in Small Cell-Transformed EGFR-Mutated Lung Adenocarcinoma: A Case Report. | JTO clinical and research reports | 2026 | 单病例报告小细胞转化肺腺癌多线治疗后使用 tarlatamab 获益 10 个月，进展时转为 DLL3 阴性肉瘤样癌，提示谱系演化相关耐药。 |
| 4 | Initial Dose Tarlatamab-Associated Tumour Lysis Syndrome in Small Cell Lung Cancer: A Case Report. | Respirology case reports | 2026 | 单病例报告高肿瘤负荷复发 SCLC 在 tarlatamab 首剂后发生致死性肿瘤溶解综合征，提示需强化预防与监测。 |
| 5 | Successful Tarlatamab Rechallenge After Recurrent High-Grade Cytokine Release Syndrome in Chromothripsis-Mediated SCLC: A Case Report. | JTO clinical and research reports | 2026 | 单病例报告两次阶梯剂量后出现高级别 CRS，但早期影像已明显缓解，继续治疗后 CRS 未再复发。 |
| 6 | Life-Threatening Prolonged ICANS Following Tarlatamab Treatment in Extensive-Stage Small Cell Lung Cancer With Brain Metastases: A Case Report. | Respirology case reports | 2026 | 单病例报告伴未识别脑转移的 ES-SCLC 在 tarlatamab 后发生 4 级延长性 ICANS 和癫痫，提示未治疗颅内病灶可能增加风险。 |
| 7 | Discrepant Intracranial and Extracranial Responses to Tarlatamab in Relapsed Small-Cell Lung Cancer With Untreated Brain Metastases: A Case Report. | Respirology case reports | 2026 | 单病例报告tarlatamab 使颅外病灶明显缩小，但未治疗脑转移进展，显示颅内外疗效可能不一致。 |
| 8 | A Novel Approach to Targeting DLL3 with Tarlatamab in a Patient with Medullary Thyroid Carcinoma after Progression on Selpercatinib. | Thyroid | 2026 | 单病例报告RET 改变髓样甲状腺癌接受 tarlatamab 后经历可控的 CRS/ICANS，并达到持续完全缓解。 |
| 9 | First Documented Response to Tarlatamab in a Patient With Transformed SCLC Without Actionable Gene Alteration: Case Report. | JTO clinical and research reports | 2026 | 单病例报告无可靶向基因改变的肺腺癌转化 SCLC 多线治疗后使用 tarlatamab，获得约 4 个月缓解及症状改善。 |
| 10 | Marked and Durable Response to DLL3-Directed T-Cell Engager Tarlatamab in a Patient With Metastatic Pulmonary Large Cell Neuroendocrine Carcinoma: A Case Report. | Clinical lung cancer | 2026 | 单病例报告PubMed 未提供摘要；公开索引显示转移性肺 LCNEC 患者接受 tarlatamab 后获得显著且持久的临床反应。 |
| 11 | Brief Report: Low Delta-Like Ligand 3 Expression and T-Cell Exhaustion Drive Resistance to Tarlatamab Combined With Anti-Programmed Cell Death Protein 1 in SCLC. | Journal of thoracic oncology | 2026 | 2病例短报告两例患者显示 tarlatamab 联合抗 PD-1 后的获得性耐药与低 DLL3、表型转变及免疫抑制微环境相关。 |
| 12 | Efficacy and safety of tarlatamab, a DLL3-targeted bispecific T-cell engager, in a patient with advanced esophageal small-cell neuroendocrine carcinoma: a case report. | Immunotherapy | 2026 | 单病例报告食管小细胞神经内分泌癌二线使用 tarlatamab 后肝、脑转移灶完全消退，且未见药物相关不良事件。 |
| 13 | Tumor Inflammation-Associated Neurotoxicity Masquerading as Severe Immune Effector Cell-Associated Neurotoxicity Syndrome in a Patient With SCLC Treated With Tarlatamab: A Case Report. | Journal of thoracic oncology | 2026 | 单病例报告重度神经毒性最终被判断为脑转移局部炎症相关神经毒性，而非典型 ICANS，并在强化激素后逆转。 |
| 14 | Pseudoprogression Associated With T-cell Infiltration During Tarlatamab Therapy for Small-Cell Lung Cancer: A Case Report. | Cureus | 2026 | 单病例报告tarlatamab 治疗期间出现假性进展，淋巴细胞下降和 IL-6 升高可能反映肿瘤内 T 细胞浸润。 |
| 15 | Synchronous occurrence of interstitial lung disease and ICANS after tarlatamab initiation in recurrent small-cell lung cancer. | Respiratory medicine case reports | 2026 | 单病例报告复发 SCLC 启动 tarlatamab 后同步出现间质性肺病和 ICANS，补充了联合不良事件的病例经验。 |
| 16 | Flare Reaction following Tarlatamab Treatment in a Patient with Extensive-Stage Small Cell Lung Cancer: Case Report. | Case reports in oncology | 2026 | 单病例报告tarlatamab 后短暂影像恶化并伴胸腔积液，随后快速缩小，提示早期免疫激活导致 flare reaction 而非真进展。 |
| 17 | First Report of Response to Tarlatamab in a Patient With Histologic-Transformed SCLC From ALK-Rearranged NSCLC: Case Report. | JTO clinical and research reports | 2026 | 单病例报告ALK 重排 NSCLC 转化 SCLC 在多线治疗失败后使用 tarlatamab，获得持续临床获益，包括颅内反应。 |
| 18 | Rapid-onset Severe Cytokine Release Syndrome With Marked Interleukin-6 Increase and Acute Liver Injury After the First Tarlatamab Dose in SCLC: Case Report. | JTO clinical and research reports | 2025 | 单病例报告首剂 tarlatamab 后快速发生重度 CRS 和急性肝损伤，动态 IL-6 可能有助于监测毒性。 |
| 19 | Rapid disease progression and hydrocephalus following tarlatamab therapy initiation: A case report. | Respiratory medicine case reports | 2025 | 单病例报告tarlatamab 后认知障碍最终证实为脑转移进展导致的梗阻性脑积水，而非 ICANS。 |
| 20 | Early trajectory of inflammatory cytokines following tarlatamab administration in three advanced SCLC patients. | Cancer immunology, immunotherapy | 2025 | 3病例报告3 例 SCLC 的细胞因子追踪显示 CRS 时多种炎症因子动态升高，反映复杂的免疫激活网络。 |
| 21 | Brain Atrophy and Leukoencephalopathy Following Tarlatamab: Case Report. | Respirology case reports | 2025 | 单病例报告脑转移灶缩小的同时出现脑萎缩、脑室扩大及白质脑病，提示放疗和 tarlatamab 相关神经事件。 |
| 22 | Safe Treatment of an Extensive-Stage Small-Cell Lung Cancer With Tarlatamab in an Orthotopic Heart Transplantation Patient: A Case Report. | Cureus | 2025 | 单病例报告心脏移植受者接受 4 次 tarlatamab 治疗未见移植物排斥或功能障碍。 |
| 23 | Tarlatamab-Induced Tumor Lysis Syndrome in Small Cell Carcinoma: Case Series. | Clinical lung cancer | 2026 | 病例系列PubMed 未提供摘要；病例系列指出 TLS 是 tarlatamab 罕见但潜在致命的毒性，建议高肿瘤负荷或铂耐药 SCLC 中监测。 |
| 24 | Early Pseudoprogression After Tarlatamab in Small-Cell Lung Cancer: A Case Report. | Respirology case reports | 2025 | 单病例报告首剂后出现骨痛、肿瘤及胸腔积液短暂增大，随后胸腹病灶回缩，支持早期假性进展。 |
| 25 | Efficacy and Safety of Tarlatamab in a Patient With Advanced Delta-Like Ligand 3-Positive Large Cell Neuroendocrine Lung Carcinoma and Untreated Brain Metastases: A Case Report. | JCO precision oncology | 2025 | 单病例报告公开索引信息显示，伴未治疗脑转移的 DLL3 阳性 LCNEC 患者发生 3 级 CRS 后仍获得包括脑内完全缓解在内的显著疗效，并成功再挑战。 |
| 26 | Rapid Intracranial Response With Tarlatamab in Patients With Untreated Brain Metastases From SCLC-A Real-World Case Series: Case Report. | Journal of thoracic oncology | 2025 | 10病例真实世界病例系列10 例未治疗脑转移复发 SCLC 中，90% 达到临床反应或稳定，部分患者脑转移快速显著缓解，可能延迟全脑放疗。 |
| 27 | Tarlatamab Rechallenge After Grade 3 Cytokine Release Syndrome Leading to Tumor Regression in Two Weeks and Reopening of a Collapsed Lung: A Case Report. | Clinical lung cancer | 2025 | 单病例报告PubMed 未提供摘要；题名显示患者发生 3 级 CRS 后成功再挑战，2 周内肿瘤回缩并重新开放塌陷肺。 |
| 28 | First Report of Response to Tarlatamab in a Patient With DLL3-Positive Pulmonary Carcinoid: Case Report. | JTO clinical and research reports | 2024 | 单病例报告DLL3 阳性转移性非典型肺类癌多线进展后使用 tarlatamab 获得临床反应，提示其可能适用于其他肺神经内分泌肿瘤。 |
| 29 | Tarlatamab for Large Cell Neuroendocrine Carcinoma in a Young Adult: A Case Report. | JTO clinical and research reports | 2024 | 单病例报告20 岁转移性肺 LCNEC 患者接受 tarlatamab 后虽出现短暂 CRS，但获得部分缓解。 |